vTv Therapeutics Inc. (VTVT): Key fundamentals of VTVT

0
49

vTv Therapeutics Inc. (NASDAQ:VTVT) changes shares on Monday trading session, with a change of 0.50% or $0.01 shares. The trading starts at $3.04 and closed at $2.76 throughout the day. The trading session low price was $2.70 and day high was $3.14 on Monday, June 15. After the session, the Healthcare sector daily volume shifted to 2.74 million while its average volume is 327.94K. In other hand, the VTVT market cap reached to $180.52M. While, its current target price is $2.77 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -8.58% and down -8.58% for month. Its quarterly performance was 50.95% above, while its half year performance is up 82.84%. VTVT yearly performance stood at positive 99.28% and rise 62.94% for year-to-date. Current recommendation for vTv Therapeutics Inc. is 2.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. VTVT EPS (TTM) for 12-month is -0.47. EPS for this year is 14.90%, while for the next year its value is -0.59. Its EPS Q/Q reached 57.80%. It has an EPS of 11.70% up for past five years.

Let’s take a look on the analyst recommendations on VTVT for the current month and previous month. For the current month, 2 of 2 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $6.00-$8.00. Average target price for VTVT was reached at $7.00.

Royal Bank of Canada, Frazier Management LLC and Vanguard Group, Inc. (The) are the top three holders in vTv Therapeutics Inc. (VTVT) stock. On Mar 30, 2020, Royal Bank of Canada has 3.25 million shares which valued 6.21 million. On Mar 30, 2020, Frazier Management LLC owned 1.06 million shares which valued at 2.03 million. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 0.31 million shares which valued at 0.59 million. In the end, Vanguard Group, Inc. (The) have 0.69% shares outstanding of vTv Therapeutics Inc. (VTVT) on Mar 30, 2020. The insider ownership moved to 0.10% and institutional holding shifted to 12.50%.

The company posted an EPS (TTM) of -0.47. According to the most recent quarter report on (Mar 2020), 1 analysts estimated an average EPS of -0.1, while -0.15 EPS posted a year ago period. Analyst Estimated EPS for VTVT published in the report was -0.1–0.1 during the same period. Comparing with last year, the average estimated EPS was -0.15 which is lower than -0.13 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for VTVT rise 36.65% for period of 200 days. SMA for 50 days was 12.10% which is showing green signal, while SMA-20 was -4.10%. The moving average value for vTv Therapeutics Inc. (VTVT) is 2.2959 and 2.6430 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in VTVT stock. On May 15, KOZLOV HERSH, Director, bought 10,000 trading shares at the cost of $3.00, which valued at 30000.0. On May 12, PERELMAN RONALD O, 10% Owner, bought 625,000 shares at the cost of $1.60, with total shares of 34,731,212. On Feb 25, PERELMAN RONALD O, 10% Owner, bought 1,250,000 shares at the cost of 1.60. After this transaction, PERELMAN RONALD O total shares reached to 34,106,212 which valued at 2.0 million.